Abstract:Background: There are several anticoagulation strategies are suggested for patients with acute venous thromboembolism (VTE), however proof, especially for cancer-associated VTE, is lacking of which strategy is optimal choice. We aimed to compare efficacy and safety outcomes among various anticoagulation strategies for patients with VTE using a systematic review and network meta-analysis. Methods: A systematic literature search was conducted using PUBMED, EMBASE, and Cochrane Library Central Register of Controlled Trials and clinical trial registries from inception through June 1, 2021. We search for randomized clinical trials (RCTs) comparing the recurrent VTE and bleeding outcomes of various anticoagulation strategies (low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux combined with vitamin K antagonists(VKA)); direct oral anticoagulants) for patients with acute VTE(noncancer or cancer-associated). Extraction of clinical outcomes were performed independently by two authors. A Bayesian network meta-analysis was applied to analyze the data. The primary efficacy endpoint was recurrent VTE episodes, the primary safety endpoint was major bleeding episodes. Secondary efficacy endpoints were fatal recurrent venous thromboembolism, the secondary safety endpoints were fatal bleeding episodes, all-cause mortality and major gastrointestinal bleeding. Results: 12117 citations were identified, 9850 unique citations, 54 RCTs met the inclusion criteria. Included trials recruited 49952 VTE participants with cancer or non-cancer. The findings showed that UFH-VKA likely increases recurrent VTE compared to LMWH-VKA (hazard ratio ((HR) 1·44(1·16,1·80), apixaban was probably the most effective strategy (surface under the cumulative ranking curve (SUCRA) 87·6%). Subgroup analysis for VTE patients with cancer shown that LMWH (HR 0·61(0·40,0·89)) and apixaban (HR 0·40(0·21,0·66)) were associated with less recurrent VTE events compared with LMWH-VKA. Apixaban (HR 0·44(0·24,0·73)) lowered the rate of major bleeding compared with the LMWH–VKA. The apixaban was probably the safest strategy (SUCRA 96·5%). For patients with cancer-associated acute VTE, although apixaban group experienced less major bleeding events compared with LMWH-VKA, it was not statically significant (HR 0·80(0·36,1·55)). Interpretation: Apixaban seems to be superior to other anticoagulation strategies for treatment of VTE with cancer. Funding: This work received research grant from The Second Hospital of Anhui Medical University(Hefei, Anhui 230601, China). Grant number: LBSART202007. Declaration of Interest: None to declare.

Pharmacological Thromboprophylaxis for VTE Post-Endovenous Ablation of Varicose Veins: Network Meta-Analysis

Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis

Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach

Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data

Anticoagulants for the treatment of isolated lower limb superficial vein thrombosis a Bayesian network meta-analysis of randomized controlled trials

Thromboprophylaxis after knee arthroscopy does not decrease the risk of deep vein thrombosis: a network meta-analysis

Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery

Bleeding Risks with Novel Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation: a Systematic Review and Network Meta-Analysis.

Safety of Anticoagulation When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis

Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis

Factor Xa Inhibitors and Low Molecular Weight Heparins in Perioperative Surgical Thromboprophylaxis: A Network Meta-Analysis

New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis

Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis

Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis

Reducing the Risk of Venous Thromboembolism Following Superficial Endovenous Treatment: A UK and Republic of Ireland Consensus Study

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: a systemic review and meta-analysis

Anticoagulation for the Treatment of Acute Venous Thromboembolism a Systematic Review and Network Meta-Analysis

Efficacy and safety of commonly used thromboprophylaxis agents following hip and knee arthroplasty

Primary Prophylaxis for Venous Thromboembolism in Ambulatory Cancer Patients: a Systematic Review and Network Meta-Analysis.

Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis